NDA 220414 · Emd Serono
Pimjetmi
Pimicotinib · Oral
NovelCDER novel approval, Nov 13, 2026: To treat adults with symptomatic tenosynovial giant cell tumors in whom surgical resection may cause worsening functional limitation or severe morbidity
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Nov 10, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
12
1 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat adults with symptomatic tenosynovial giant cell tumors in whom surgical resection may cause worsening functional limitation or severe morbidity
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- PIMJETMI · PIMICOTINIB 50MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pimicotinib" as an intervention, any sponsor and status, largest first.
- Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)Pivotal-lookingActive, not recruiting
Abbisko Therapeutics Co, LtdIndustry
NCT05804045 · 94 participants · Start Apr 27, 2023 · Primary completion Sep 23, 2024
Drug: Pimicotinib(ABSK021); Placebo · For: Tenosynovial Giant Cell Tumor; Pigmented Villonodular Synovitis; Giant Cell Tumor of Tendon Sheath
Sites: Beverly Hills, California; Durham, California; Detroit, Michigan · 40 sites in all
- Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell TumorNot yet recruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT07707882 · 84 participants (planned) · Start Oct 1, 2027 · Primary completion Sep 30, 2029
Drug: Pimicotinib · For: Tenosynovial Giant Cell Tumor, Diffuse
Sites: Hangzhou, China
Abbisko Therapeutics Co, LtdIndustry
NCT06111274 · 82 participants (planned) · Start Oct 17, 2023 · Primary completion Dec 30, 2025
Drug: Pimicotinib (ABSK021) · For: Advanced Pancreatic Cancer
Sites: Shanghai, China; Chengdu, China; Ha’erbin, China · 5 sites in all
- A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)Enrolling by invitation
Abbisko Therapeutics Co, LtdIndustry
NCT06186804 · 64 participants (planned) · Start May 30, 2023 · Primary completion Oct 30, 2026
Drug: ABSK021 · For: cGvHD
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 14 sites in all
Abbisko Therapeutics Co, LtdIndustry
NCT06779253 · 39 participants · Start Mar 14, 2025 · Primary completion Apr 4, 2025
Drug: pimicotinib capsules · For: Healthy Subjects
Sites: Jinan, China
- A Study to Evaluate the the Bioequivalence of Two Different Pimicotinib Capsules in Healthy SubjectsCompleted
Abbisko Therapeutics Co, LtdIndustry
NCT07126249 · 38 participants · Start May 13, 2025 · Primary completion Jun 6, 2025
Drug: pimicotinib capsules · For: Pharmacokinetics
Sites: Changchun, China
Abbisko Therapeutics Co, LtdIndustry
NCT06694948 · 26 participants · Start Dec 10, 2024 · Primary completion Jan 3, 2025
Drug: pimicotinib capsules · For: Pharmacokinetics
Sites: Changchun, China
Abbisko Therapeutics Co, LtdIndustry
NCT06562946 · 24 participants · Start Sep 20, 2024 · Primary completion Dec 30, 2024
Drug: Pimicotinib · For: Pharmacokinetics
Sites: Changchun, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial.
Xu H, Niu X, Ravi V, et al. · Lancet 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Emd Serono
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.